Clinical Trial Search

Phase 3 N=13 Collection of Bone Marrow From Donors Treated With or Without Filgrastim

Healthy Stem Cell Donor · No Evidence of Disease

Primary: Percentage of Participants With Short-term Adverse Events in G-CSF (Filgrastim) Stimulated Bone Marrow (G-BM) Donors — 0 Percentage of patients

Children's Oncology Group Results Feb 2020 0.0% serious AE View details

Phase 3 N=123 Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study

Esophageal Carcinoma · Esophagogastric Junction Carcinoma

Primary: Overall Survival (OS) in All Participants — 8.4; 5.6 Months — p=0.0015

Merck Sharp & Dohme LLC Results Feb 2020 37.7% serious AE View details

Phase 3 N=91 Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)

Partial Onset Seizures

Primary: Percentage of Participants With Partial-onset Seizures (POS) Who Achieved Seizure-free Status During the 26-week Maintenance Period of 4 mg Perampanel — 63.0 percentage…

Eisai Co., Ltd. Results Feb 2020 14.6% serious AE View details

Phase 3 N=138 Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics

Pouchitis

Primary: Proportion of Patients With Endoscopic Remission — 3; 3 Participants

Atlantic Pharmaceuticals Ltd Results Feb 2020 4.4% serious AE View details

Phase 3 N=122 Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Iron Deficiency Anaemia · Iron Deficiency Anemia

Primary: Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL) — 5; 42 Participants — p=<0.0001

Pharmacosmos A/S Results Feb 2020 0.8% serious AE View details

Phase 3 N=123 Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Iron Deficiency Anaemia · Iron Deficiency Anemia

Primary: Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL) — 5; 45 Participants — p=<0.0001

Pharmacosmos A/S Results Feb 2020 0.8% serious AE View details

Phase 3 N=157 2% Chlorhexidine Gluconate Skin Cloths to Prevent SSI in Spine Surgery Patients

Surgical Site Infections · Post Operative Complication

Primary: Participants With Surgical Site Infection Development at 30 Days Post-operative — 5; 5 Participants — p=0.456

Vanderbilt University Results Feb 2020 0.0% serious AE View details

Phase 3 N=250 Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD

Anemia, Iron-Deficiency · Inflammatory Bowel Disease · Crohn's Disease

Primary: Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12 — 84; 105; 41; 20 Participants — p=0.298

Shield Therapeutics Results Feb 2020 6.5% serious AE View details

Phase 3 N=2,436 A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Asthma

Primary: Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 — 0.024; 0.120; 0.134; 0.076 Liters — p=<0.001

GlaxoSmithKline Results Feb 2020 5.4% serious AE View details

Phase 3 N=225 Efficacy Study Of Tofacitinib In Pediatric JIA Population

Juvenile Idiopathic Arthritis

Primary: Double Blind Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International…

Pfizer Results Feb 2020 2.5% serious AE View details

Phase 3 N=636 Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.

HIV Infections

Primary: Percentage of Participants With Plasma HIV-1 RNA <200 Copies/mL 48 Weeks After Randomisation — 92.2; 94.1 percentage of participants — p=0.05

Kirby Institute Results Feb 2020 7.6% serious AE View details

Phase 3 N=703 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis

Erosive Esophagitis

Primary: Percentage of Participants With Recurrence of Erosive Esophagitis as Confirmed on Endoscopy After the 24-week Maintenance Phase — 13.3; 12.3; 25.5 percentage of…

Takeda Results Feb 2020 4.3% serious AE View details

Phase 3 N=1,488 A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

Acne Vulgaris

Primary: The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12. — 16.39; 12.74 Lesion Count

Vyne Therapeutics Inc. Results Feb 2020 0.3% serious AE View details

Phase 3 N=605 A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures

Epilepsy, Partial Seizures · Epilepsy, Primary Generalized Tonic-Clonic Seizures

Primary: Number of Participants With Treatment Emergent Adverse Events (AEs), Treatment Emergent Serious Adverse Events (SAEs), Treatment Related AEs and Treatment Related SAEs…

Pfizer's Upjohn has merged with Mylan to form… Results Feb 2020 12.7% serious AE View details

Phase 3 N=108 Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

Hypereosinophilic Syndrome

Primary: Percentage of Participants Who Experienced an HES Flare or Who Withdrew From the Study During the 32-Week Study Treatment Period — 56; 28 Percentage of participants…

GlaxoSmithKline Results Feb 2020 17.6% serious AE View details